FTD Microglia Role: Protective vs Destructive Mechanism Study
Background and Rationale
Validation experiment to determine whether microglia play a predominantly protective or destructive role in frontotemporal dementia (FTD), using conditional microglial depletion and repopulation in progranulin-deficient (GRN-/-) mice.
Protocol: GRN-/- mice (FTD model) at 6 months (pre-symptomatic) and 12 months (symptomatic), n=20 per group: (1) PLX5622 (CSF1R inhibitor) diet for microglial depletion (14 days), then normal diet for repopulation (14 days). (2) TREM2-activating antibody treatment for microglial activation enhancement. (3) Vehicle control. (4) Wild-type littermates. Assessments: behavioral tests (marble burying, social interaction, Morris water maze), cytokine profiling (multiplex ELISA), lipofuscin/lysosomal storage (histology), synaptic density (Golgi staining), single-cell RNA-seq of repopulated microglia, CSF neurofilament light chain.
...FTD Microglia Role: Protective vs Destructive Mechanism Study
Background and Rationale
Validation experiment to determine whether microglia play a predominantly protective or destructive role in frontotemporal dementia (FTD), using conditional microglial depletion and repopulation in progranulin-deficient (GRN-/-) mice.
Protocol: GRN-/- mice (FTD model) at 6 months (pre-symptomatic) and 12 months (symptomatic), n=20 per group: (1) PLX5622 (CSF1R inhibitor) diet for microglial depletion (14 days), then normal diet for repopulation (14 days). (2) TREM2-activating antibody treatment for microglial activation enhancement. (3) Vehicle control. (4) Wild-type littermates. Assessments: behavioral tests (marble burying, social interaction, Morris water maze), cytokine profiling (multiplex ELISA), lipofuscin/lysosomal storage (histology), synaptic density (Golgi staining), single-cell RNA-seq of repopulated microglia, CSF neurofilament light chain.
Primary Outcome: Behavioral and neuropathological outcomes after microglial depletion-repopulation vs. activation enhancement. Success Criteria: If depletion-repopulation improves outcomes, microglia are net-destructive in GRN-/- FTD. If TREM2 activation improves outcomes, microglia are net-protective when properly activated. Model System: GRN-/- C57BL/6 mice. Expected Timeline: 10 months. Estimated Cost: $250K.
This experiment directly tests predictions arising from the following hypotheses:
- TREM2-mediated microglial tau clearance enhancement
- Microglial Purinergic Reprogramming
- Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators
- Purinergic P2Y12 Inverse Agonist Therapy
- Microglial Efferocytosis Enhancement via GPR32 Superagonists
Experimental Protocol
Subject Selection: Breed GRN-/- mice and wild-type littermates. At 6 months (pre-symptomatic, n=80) and 12 months (symptomatic, n=80), randomly assign to four treatment groups (n=20 each): PLX5622 depletion/repopulation, TREM2 antibody activation, vehicle control, and wild-type control. 2. Baseline Assessment: Conduct behavioral battery including marble burying test (30 marbles, 30min), social interaction chamber (10min sessions), and Morris water maze (5 days acquisition, 24h probe trial). Collect baseline CSF via cisterna magna puncture for neurofilament light chain quantification by ELISA. 3. Treatment Phase: Group 1 receives PLX5622-formulated chow (1200mg/kg) for 14 days to achieve >95% microglial depletion (confirmed by Iba1 immunostaining), followed by normal chow for 14 days repopulation. Group 2 receives TREM2-activating antibody (AL002c, 30mg/kg i.p., twice weekly for 4 weeks). Groups 3-4 receive respective vehicle controls. 4. Interventional Monitoring: Weekly body weight, neurological scoring, and microglial depletion confirmation via Iba1 staining in pilot animals (n=3 per timepoint). 5. Endpoint Analysis: Repeat behavioral assessments at day 28. Sacrifice animals for brain harvest. Process tissue for: cytokine multiplex ELISA (IL-1β, TNF-α, IL-6, IL-10, TGF-β), lipofuscin quantification via Sudan Black staining, synaptic density analysis using Golgi-Cox staining and spine counting, single-cell RNA-sequencing of FACS-sorted CD11b+ microglia (10x Genomics platform). Quantify CSF neurofilament light chain levels.Expected Outcomes
Primary Outcomes: If microglia are predominantly protective, PLX5622 depletion should worsen behavioral deficits by 25-40% in marble burying (increased stereotypy), social interaction (reduced interaction time), and spatial memory (increased escape latency, reduced probe trial performance). CSF neurofilament levels should increase by 30-50%, indicating enhanced neurodegeneration. Conversely, TREM2 activation should improve behavioral scores by 20-30% and reduce neurofilament levels.
Secondary Outcomes: Protective microglial role would show: increased pro-inflammatory cytokines (IL-1β, TNF-α 2-3x elevation) and decreased anti-inflammatory markers (IL-10, TGF-β 40-60% reduction) after depletion; enhanced lipofuscin accumulation (50-70% increase) and reduced synaptic density (20-35% decrease) following microglial loss. Single-cell RNA-seq should reveal repopulated microglia exhibit altered transcriptional profiles with reduced phagocytic and debris-clearance signatures.
Destructive Role Prediction: Opposite patterns would emerge - microglial depletion improving outcomes, activation worsening pathology, suggesting microglia drive neurodegeneration in GRN-/- models through excessive inflammatory activation and synaptic pruning.
Success Criteria
Primary Success Threshold: Statistically significant (p<0.05, two-way ANOVA with Tukey post-hoc) difference of ≥25% between PLX5622 and vehicle groups in at least 2 of 3 behavioral measures, with consistent directional changes across all assessments.
Effect Size Requirements: Cohen's d ≥0.8 for primary behavioral endpoints, with 95% confidence intervals not crossing zero.
Sample Size Validation: Minimum n=15 per group completing protocol (25% attrition allowance), with power analysis confirming 80% power to detect 30% differences.
Mechanistic Validation: CSF neurofilament changes must correlate significantly (r≥0.6, p<0.01) with behavioral outcomes. Cytokine profile changes ≥2-fold in ≥3 markers with consistent pro- or anti-inflammatory patterns.
RNA-seq Criteria: Differential gene expression analysis revealing ≥100 significantly altered genes (FDR<0.05, log2FC≥1) in repopulated vs. control microglia, with pathway enrichment analysis confirming microglial activation/phagocytosis signatures (p<0.001).
Reproducibility Standard: Results must replicate across both age groups (6-month and 12-month cohorts) with consistent directional effects, establishing temporal validity of microglial role determination.